Employers can take the lead in addressing health disparities and implementing strategies to serve vulnerable populations.

By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.

An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...

Express Scripts ClearNetwork offers employers and health plans a new option for simple, “cost-plus” pharmacy pricing for brand, generic, and specialty medications.

Rise in cancer incidence, technological advancements and health care costs will have a significant impact on health outcomes and employers’ bottom line.

Over 125 million Americans suffer from chronic conditions, costing the U.S. over $3.4 trillion annually. This topic was the focus of a breakout session at Outcomes+ 2022.

Drug formularies are critical to combat the estimated $16 billion wasted each year on low value drugs that do not improve health outcomes.

The team focuses on highly complex medications, including treatments for cancer, neurological diseases, pulmonary conditions, and bleeding disorders.